Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (17)

2022

  1. The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents

    ACS Pharmacology and Translational Science, Vol. 5, Núm. 11, pp. 1097-1108

2021

  1. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

    Molecular Cancer Therapeutics, Vol. 20, Núm. 4, pp. 641-654

2020

  1. Acetylcholinesterase inhibition of diversely functionalized quinolinones for alzheimer’s disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 11, pp. 1-20

  2. Automated Synthesis of New Quinoxalinetacrines

    ChemistrySelect, Vol. 5, Núm. 21, pp. 6491-6493

  3. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Chromenones as Multineurotargeting Inhibitors of Human Enzymes

    ACS Omega, Vol. 4, Núm. 26, pp. 22161-22168

  2. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 121-130

  3. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

    The Lancet, Vol. 394, Núm. 10193, pp. 131-138

  4. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

    AAPS Journal, Vol. 21, Núm. 2

2018

  1. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 296-303

  2. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2017

  1. Characterizing gemcitabine effects administered as single agent or combined with carboplatin in mice pancreatic and ovarian cancer xenografts: A semimechanistic pharmacokinetic/pharmacodynamics tumor growth-response model

    Journal of Pharmacology and Experimental Therapeutics, Vol. 360, Núm. 3, pp. 445-456

2009

  1. A global benchmark study using affinity-based biosensors

    Analytical Biochemistry, Vol. 386, Núm. 2, pp. 194-216

1999

  1. Asymmetric Michael addition reactions using ethyl (S)-4,4- dimethylpyroglutamate as a chiral auxiliary

    Tetrahedron Letters, Vol. 40, Núm. 8, pp. 1575-1578

1998

  1. Enantiospecific synthesis of (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic acid by a modified Corey-Link reaction

    Tetrahedron Letters, Vol. 39, Núm. 50, pp. 9305-9308

1997

  1. Asymmetric synthesis of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740)

    Tetrahedron Asymmetry, Vol. 8, Núm. 4, pp. 511-514

1995

  1. Conformationally constrained ACPD analogues. Synthesis and resolution of 3-aminobicyclo[3,3,0]octane-1,3-dicarboxylic acids

    Tetrahedron, Vol. 51, Núm. 11, pp. 3271-3278